Laying the Foundation for Real-world Evidence Studies: a Case Study from Newfoundland and Labrador

Overview

Journal Int J Popul Data Sci

Specialty Public Health

Date 2023 Aug 31

PMID 37650031

Authors

Winifred Badaiki

Evelyn Pyper

Kendra Lester

Janelle Skeard

Michelle Penney

Janey Shin

Brenda Fisher

Huong Hew

Susanne Gulliver

Wayne Gulliver

Proton Rahman

Affiliations

Soon will be listed here.

Abstract

The Janssen and Newfoundland and Labrador Health Innovation Partnership (JANL-HIP) was established to carry out Real-World Evidence (RWE) projects to generate evidence about disease pathways, healthcare delivery, the effects of clinical interventions. Doing so will support and influence clinical decision-making in Newfoundland and Labrador (NL). This case study describes the foundational elements necessary for a real-world evidence generation project in NL and may provide learning for the effective execution of real-world studies in other jurisdictions. It uses an ongoing project in psoriatic disease in NL to illustrate the partnership and the benefits of RWE studies. Ultimately, the JANL-HIP RWE project aims to inform decisions that will drive improvements in health outcomes, system delivery, and policy mutually beneficial to health ecosystem stakeholders.

Citing Articles

"Unnatural resources?": parallels and distinctions between the Newfoundland Genome and traditional resource sectors.

Skeard J J Community Genet. 2024; 15(4):449-459.

PMID: 38896389 PMC: 11410739. DOI: 10.1007/s12687-024-00715-w.

References

Ark T, Kesselring S, Hills B, McGrail K . Population Data BC: Supporting population data science in British Columbia. Int J Popul Data Sci. 2020; 4(2):1133. PMC: 7480325. DOI: 10.23889/ijpds.v5i1.1133. View

Chan K, Nam S, Evans B, de Oliveira C, Chambers A, Gavura S . Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. BMJ Open. 2020; 10(1):e032884. PMC: 6955501. DOI: 10.1136/bmjopen-2019-032884. View

Gomez-Ulloa D, Amonkar M, Kothari S, Cheung W, Chau I, Zalcberg J . Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. BMC Gastroenterol. 2020; 20(1):133. PMC: 7201990. DOI: 10.1186/s12876-020-01232-z. View

Camm A, Fox K . Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants. Open Heart. 2018; 5(1):e000788. PMC: 5922572. DOI: 10.1136/openhrt-2018-000788. View

Badaiki W, Penney M, Pyper E, Lester K, Skeard J, Shin J . Real World Studies of Psoriasis and Mental Illness in Newfoundland and Labrador. J Cutan Med Surg. 2022; 26(5):494-501. PMC: 9476230. DOI: 10.1177/12034754221117736. View

Han C, Robinson Jr D, Hackett M, Paramore L, Fraeman K, Bala M . Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006; 33(11):2167-72. View

Rahman P, Baer P, Keystone E, Choquette D, Thorne C, Haraoui B . Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry. BMC Rheumatol. 2020; 4:46. PMC: 7501619. DOI: 10.1186/s41927-020-00145-4. View

Neimann A, Shin D, Wang X, Margolis D, Troxel A, Gelfand J . Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006; 55(5):829-35. DOI: 10.1016/j.jaad.2006.08.040. View

Martani A, Genevieve L, Pauli-Magnus C, McLennan S, Elger B . Regulating the Secondary Use of Data for Research: Arguments Against Genetic Exceptionalism. Front Genet. 2020; 10:1254. PMC: 6951399. DOI: 10.3389/fgene.2019.01254. View

10.

Gladstone J, Chhibber S, Minhas J, Neish C, Sarah Power G, Lan Z . Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study. Headache. 2021; 62(1):78-88. PMC: 9298790. DOI: 10.1111/head.14218. View

11.

Peters M, van der Horst-Bruinsma I, Dijkmans B, Nurmohamed M . Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004; 34(3):585-92. DOI: 10.1016/j.semarthrit.2004.07.010. View

12.

Kim H, Kim J . Proceed with Caution When Using Real World Data and Real World Evidence. J Korean Med Sci. 2019; 34(4):e28. PMC: 6345637. DOI: 10.3346/jkms.2019.34.e28. View

13.

Ritchlin C, Colbert R, Gladman D . Psoriatic Arthritis. N Engl J Med. 2017; 376(10):957-970. DOI: 10.1056/NEJMra1505557. View

14.

Nazha B, Yang J, Owonikoko T . Benefits and limitations of real-world evidence: lessons from mutation-positive non-small-cell lung cancer. Future Oncol. 2020; 17(8):965-977. DOI: 10.2217/fon-2020-0951. View

15.

Mease P, Gladman D, Gomez-Reino J, Hall S, Kavanaugh A, Lespessailles E . Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. ACR Open Rheumatol. 2020; 2(8):459-470. PMC: 7437129. DOI: 10.1002/acr2.11156. View

16.

Schlegel D, Ficheur G . Secondary Use of Patient Data: Review of the Literature Published in 2016. Yearb Med Inform. 2017; 26(1):68-71. PMC: 6250993. DOI: 10.15265/IY-2017-032. View

17.

Blonde L, Khunti K, Harris S, Meizinger C, Skolnik N . Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther. 2018; 35(11):1763-1774. PMC: 6223979. DOI: 10.1007/s12325-018-0805-y. View

18.

Janssen P, Saxell L, Page L, Klein M, Liston R, Lee S . Outcomes of planned home birth with registered midwife versus planned hospital birth with midwife or physician. CMAJ. 2009; 181(6-7):377-83. PMC: 2742137. DOI: 10.1503/cmaj.081869. View

19.

Wijnands J, Zhu F, Kingwell E, Fisk J, Evans C, Marrie R . Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry. 2018; 89(10):1050-1056. DOI: 10.1136/jnnp-2017-317493. View

20.

Cios K, Moore G . Uniqueness of medical data mining. Artif Intell Med. 2002; 26(1-2):1-24. DOI: 10.1016/s0933-3657(02)00049-0. View